5 news items
Viking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
VKTX
4 Jun 24
and cash resources. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and adversely
EXCLUSIVE: Roundhill Investments Launches Weight Loss ETF For Exposure To Blockbuster Drugs Like Ozempic
AMGN
HIMS
LLY
21 May 24
this to have a material impact on the industry as we're forecasting prices to decline as the industry matures and more drugs come to market,” he
Ligand Reports First Quarter 2024 Financial Results
AMGN
CASI
JAZZ
7 May 24
use our investor relations website and X as a means of disclosing material non-public information and for complying with our disclosure obligations
Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
VKTX
24 Apr 24
to differ materially and adversely and reported results should not be considered as an indication of future performance. These risks and uncertainties
Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735
VKTX
26 Mar 24
prospects. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and adversely
- Prev
- 1
- Next